Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04207086
Title A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)
Acronym Neo PeLe
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
Melanoma Institute Australia North Sydney New South Wales 2060 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field